Nirmatrelvir; ritonavir

(Paxlovid®)

Paxlovid®

Drug updated on 12/11/2024

Dosage FormTablet (oral; nirmatrelvir 150 mg, ritonavir 100 mg)
Drug ClassSARS-CoV-2 main protease (Mpro: also referred to as 3CLpro or nsp5 protease) inhibitors and HIV-1 protease inhibitors and CYP3A inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 15 systematic review(s)/meta-analysis(es). [1-13]
  • The studies focused on adults with COVID-19, specifically analyzing the effectiveness of nirmatrelvir/ritonavir across various subgroups, including those differentiated by age (less than 65 years and 65 years or greater), vaccination status, ethnicity, and underlying high-risk conditions, showing no significant differences in treatment outcomes based on these factors, with results indicating a reduction in hospitalization and mortality across subgroups.
  • Nirmatrelvir/ritonavir demonstrated consistent efficacy in reducing hospital admissions and mortality irrespective of high-risk conditions, and its effectiveness was not influenced by vaccination status (relative risk (RR) Psubgroup = 0.47), suggesting broad applicability in the treatment of COVID-19.
  • Nirmatrelvir/ritonavir did not show a significant increase in adverse events with RR was 1.41, a 95% confidence interval (CI) of 0.92 to 2.14, and I² of 70.6% based on 4 randomized controlled trials (RCTs) involving 4,070 participants. and was associated with a moderate-certainty increase in treatment-related adverse events such as dysgeusia and diarrhea compared to standard-of-care (SOC) plus placebo (RR 2.06, 95% CI 1.44 to 2.95).
  • Serious adverse events were not significantly increased with nirmatrelvir/ritonavir (RR = 0.82; 95% CI, 0.41-1.62; I² = 0%; 3 RCTs, 3,806 persons), and the treatment may actually reduce serious adverse events when compared to SoC plus placebo (RR 0.24, 95% CI 0.15 to 0.41; low-certainty evidence).
  • Nirmatrelvir/ritonavir demonstrated effectiveness in reducing hospital admission and mortality across various subgroups, including age and vaccination status, with no significant differences observed in these populations (RR Psubgroup = 0.47) and no differences in outcomes for patients aged less than 65 years versus 65 years or greater. Additionally, treatment effectiveness was consistent regardless of high-risk conditions, with 92.1% of study participants from upper-middle-income or high-income countries.

Product Monograph / Prescribing Information

Document TitleYearSource
Paxlovid (nirmatrelvir; ritonavir) Prescribing Information.2023Pfizer Laboratories, Div Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis2024Annals of Family Medicine
Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis2024PloS One
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies2024The Journal of Antimicrobial Chemotherapy
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review2024 American Journal of Therapeutics
Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews2024The Journal of Antimicrobial Chemotherapy
Nirmatrelvir combined with ritonavir for preventing and treating COVID-192023The Cochrane Database of Systematic Reviews
Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis2023Annals of Medicine
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis2023Journal of Medical Virology
Nirmatrelvir combined with ritonavir for preventing and treating COVID-192022The Cochrane Database of Systematic Reviews
The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials2022Analysis of Randomized Controlled Trials
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis2022Canadian Medical Association Journal
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis2022Annals of Medicine
Drug treatments for covid-19: living systematic review and network meta-analysis2020British medical journal

Clinical Practice Guidelines